Novo Nordisk A/S
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Maziar Mike Doustdar
- Full Time Employees
- 68,794
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Address
- Novo Alle 1 Bagsvaerd CR Denmark 2880
- IPO Date
- Apr 30, 1981
- CIK
- 0000353278
- Website
- novonordisk.com
- Similar Companies
- Business
- Novo Nordisk A/S, a leading global healthcare company founded in 1923 and headquartered in Bagsværd, Denmark, develops, manufactures and markets pharmaceutical products and services focused on diabetes care, obesity management, rare blood disorders, growth hormone therapy and hormone replacement therapy; its core offerings include GLP-1 receptor agonists such as semaglutide branded as Ozempic and Rybelsus for type 2 diabetes and Wegovy for obesity, insulins including rapid-acting NovoLog/NovoRapid, long-acting Tresiba and Levemir, and human insulins like Novolin R, alongside hemostasis products such as NovoSeven and NovoEight for hemophilia, and growth hormone therapies; the company operates production facilities in nine countries, employs over 76,000 people and markets its products in approximately 170 countries worldwide, with majority control held by Novo Holdings A/S, a wholly owned entity of the Novo Nordisk Foundation. Recent strategic developments include the October 2025 acquisition of Akero Therapeutics for up to $5.2 billion to bolster its metabolic dysfunction-associated steatohepatitis (MASH) pipeline, a May 2025 partnership and licensing agreement with Septerna potentially worth $2.2 billion for oral small molecule therapies targeting obesity, type 2 diabetes and cardiometabolic disorders, a December 2024 collaboration with Photys Therapeutics for up to $186 million in proximity-based therapeutics for cardiometabolic targets, filing for FDA approval of a higher 7.2 mg dose of Wegovy injection in November 2025, positive phase 2 results for amycretin showing significant weight loss and HbA1c reduction in type 2 diabetes patients in November 2025, and workforce reduction of 9,000 positions or about 9% globally in September 2025 amid competitive pressures from generic entrants; the company continues expanding manufacturing capacity, including a $4.1 billion semaglutide plant in Clayton, North Carolina announced in June 2024 and acquisition of Catalent sites, while appointing Maziar Mike Doustdar as CEO effective August 2025.
Company News
Bristol Myers Squibb vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?
Lilly Cut an Obesity Drug -- but the Move Shows How High Its Bar Has Become
Could This Be Novo Nordisk's Next Billion-Dollar Weight-Loss Product?
Novo Nordisk A/S (NVO) is Attracting Investor Attention: Here is What You Should Know
NTHM's Index Rebalance Puts Thematic Rotation to Work
Pharma stock soars 150% on injectables deal with Wegovy maker Novo
Novo Nordisk to Pay Up to $1.3 Billion for Nanexa's Drug Delivery Technology
Nanexa shares soar on €1.17 billion Novo Nordisk deal for injection technology
AbbVie vs. Novo Nordisk: Which Drug Giant Stock Is a Better Buy in 2026?
Novo Nordisk: Capital Markets Day Reveals Its Next Growth Engine
Novo's new strategy hinges on something it can't manufacture: investor trust
Novo Nordisk (NVO) Falls More Steeply Than Broader Market: What Investors Need to Know
Novo's Oral Wegovy Just Revealed a Surprising Weight-Loss Signal
Novo Nordisk open to direct New York listing, CEO says
Viking's Obesity Edge May Be Staying Power, Not Weight Loss
Can Novo's Rare Disease Pipeline Add a New Growth Pillar Beyond GLP-1?
Eli Lilly Keeps Pulling Ahead—Can Novo Nordisk Catch Up?
Breakfast News: A Warning Shot for Housing?
Novo wants to change how Wall Street owns its stock: why now
Novo Nordisk open to New York listing upgrade, CEO Doustdar tells FT